fe769a85-08b2-4442-aa8f-2b587e49001d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.600
- OXIDATIVE_PHOSPHORYLATION+0.500
- ALLOGRAFT_REJECTION+0.400
- DNA_REPAIR+0.300
- MYC_TARGETS_V1+0.300
- MYC_TARGETS_V2+0.300
- IL6_JAK_STAT3_SIGNALING+0.200
- APOPTOSIS+0.100
- COMPLEMENT+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- NOTCH_SIGNALING-0.400
- ANGIOGENESIS-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- HEDGEHOG_SIGNALING-0.300
- TGF_BETA_SIGNALING-0.300
- UV_RESPONSE_DN-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- ANDROGEN_RESPONSE-0.200
- KRAS_SIGNALING_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-F7-A61S-01A-11R-A28V-07 | — | — | 0.886 |
| 2 | TCGA-T2-A6WX-01A-12R-A34R-07 | — | — | 0.876 |
| 3 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.828 |
| 4 | MNG930 | — | — | 0.817 |
| 5 | TCGA-F7-A620-01A-11R-A28V-07 | — | — | 0.813 |
| 6 | TCGA-UF-A7JT-01A-11R-A34R-07 | — | — | 0.813 |
| 7 | TCGA-OL-A66H-01A-11R-A29R-07 | — | B | 0.812 |
| 8 | a8cd01e2-f7f4-487c-8cde-4fcf21bfe0e7 | — | — | 0.812 |
| 9 | 213f702a-56fd-4ab0-940c-a71e4e01b6f8 | — | — | 0.808 |
| 10 | TCGA-D8-A1XL-01A-11R-A14M-07 | — | B | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |